iPSC-derived cartilage exosomes

About Sarcio

Sarcio is a private, pre-clinical-stage biotech developing a novel exosome-based regenerative therapy for osteoarthritis. Its core technology platform utilizes iPSC-derived cartilage to produce exosomes with targeted regenerative signals, offering a potentially disease-modifying and scalable alternative to current palliative treatments. The company is led by a seasoned team with expertise in stem cell biology, orthopedics, and biopharmaceutical commercialization, positioning it to address a massive unmet medical need in a large and growing market.

Therapeutic Areas